We are live on ! Find out more
CRSP icon

CRISPR Therapeutics

436 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 100 funds opening new positions, 129 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more capital inflows, than outflows

Capital inflows: $569M | Capital outflows: $262M

67% more first-time investments, than exits

New positions opened: 100 | Existing positions closed: 60

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

28% more repeat investments, than reductions

Existing positions increased: 129 | Existing positions reduced: 101

9% more funds holding

Funds holding: 400 → 436 (+36)

8.39% more ownership

Funds ownership: 75.4% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
436
Holders Change
+36
Holders Change %
+9%
% of All Funds
5.71%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
100
Increased
129
Reduced
101
Closed
60
Calls
$244​M
Puts
$186​M
Net Calls
+$58.2​M
Net Calls Change
+$37.5​M

CRSP Hedge Fund Activity: Q2 2025 in Review

436 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 100 funds opened new CRSP positions and 60 closed out — a net gain of 40 holders — while 129 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 436 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 400 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 100 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +40 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.